# Special Issue

# Current State of Global African Swine Fever Vaccine Development

## Message from the Guest Editors

African swine fever virus (ASFV) is the etiological agent of African swine fever (ASF), a disease affecting both wild boar and domestic pigs. ASFV now represents one of the most important concerns for society, swine exploitation and the food industry worldwide. The virulence varies among the different ASFV strains, ranging from the acute infections with 100% mortality produced by highly virulent strains, to chronic infections presenting low or no mortality induced by attenuated strains. The molecular mechanisms leading to virulence are of great importance for understanding viral pathogenesis, being a direct component in the rational design of vaccines. In this regard, a key element differentiating attenuated from virulent strains is the different ability to control host IFN-I production. Most probably, no efficient and safe vaccines against ASF will be developed without a more complete understanding of the virus–host interaction, specifically, of the viral mechanisms used to evade the host's innate immune response.

## Guest Editors

Dr. Yolanda Revilla

Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Microbes in Health and Welfare Department, c/ Nicolás Cabrera, 1, 28049 Madrid, Spain

Dr. Daniel Pérez-Núñez

Centro de Biología Molecular Severo Ochoa, CSIC-UAM, Microbes in Health and Welfare Department, c/ Nicolás Cabrera, 1, 28049 Madrid, Spain

## Deadline for manuscript submissions

closed (31 December 2022)

**Vaccines**

**an Open Access Journal by MDPI**

**Impact Factor 3.4**
**CiteScore 9.9**
**Indexed in PubMed**

mdpi.com/si/86755

*Vaccines*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

# Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

# About the Journal

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

## Author Benefits

**High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:**

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI